Alison Schlisman, MD
Geriatric Medicine · Salt Lake City, UTNPI 1265534887
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 95 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 11.5% — the pattern of someone who eats at a lot of different presentations.
Across 95 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$207
- Viiv Healthcare Company$189
- GSK$150
- AstraZeneca$146
- Exact Sciences$133
- Lilly USA, LLC$120
- plus $849 from 20 others
What the payments were for
- Food & beverage$1,794100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 9 | $207 |
| Viiv Healthcare Company | 9 | $189 |
| GSK | 10 | $150 |
| AstraZeneca | 8 | $146 |
| Exact Sciences | 7 | $133 |
| Lilly USA, LLC | 7 | $120 |
| Boehringer Ingelheim | 5 | $115 |
| Novo Nordisk | 6 | $100 |
| Astellas Pharma US Inc | 4 | $77 |
| Amgen | 4 | $73 |
| Phathom Pharmaceuticals, Inc. | 3 | $52 |
| Pfizer | 3 | $52 |
| Merck | 3 | $48 |
| Baxter Healthcare | 1 | $44 |
| Novartis | 2 | $43 |
| Sanofi-aventis U.S. LLC | 3 | $40 |
| Bayer | 2 | $38 |
| Dexcom, Inc. | 1 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Lucid Diagnostics Inc. | 1 | $20 |
| Gilead | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Boston Scientific | 1 | $16 |
| Johnson & Johnson | 1 | $14 |
How this compares
Too few geriatric medicine providers in Utahto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 65 | $103,544 |
| OzempicSemaglutide | 53 | $62,292 |
| KevzaraSarilumab | 13 | $57,894 |
| EliquisApixaban | 56 | $51,721 |
| FarxigaDapagliflozin Propanediol | 19 | $30,590 |
| VraylarCariprazine Hcl | 11 | $23,642 |
| Repatha SureclickEvolocumab | 38 | $21,251 |
| MyrbetriqMirabegron | 31 | $19,705 |
| XareltoRivaroxaban | 11 | $18,843 |
| JardianceEmpagliflozin | 13 | $16,726 |
| GemtesaVibegron | 14 | $13,877 |
| Dexlansoprazole DrDexlansoprazole | 26 | $3,583 |
| KlonopinClonazepam | 13 | $2,862 |
| Celecoxib | 71 | $2,557 |
| Gabapentin | 137 | $2,524 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $120 | $103,54465 claims |
| Novo NordiskOzempic | $100 | $62,29253 claims |
| PfizerEliquis, Paxlovid | $52 | $53,08881 claims |
| AstraZenecaFarxiga | $146 | $30,59019 claims |
| AbbVieVraylar, Synthroid | $207 | $25,38736 claims |
| Astellas Pharma US IncMyrbetriq | $77 | $19,70531 claims |
| Johnson & JohnsonXarelto | $14 | $18,84311 claims |
| Boehringer IngelheimJardiance | $115 | $16,72613 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $16 | $13,87714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few geriatric medicine providers in Utahon file to place this against a meaningful peer group, so we don't.
Other geriatric medicine in Salt Lake City
- Danesh RahimiSalt Lake City$2K
- Ronak IqbalSalt Lake City$1K
- Sumati GuptaSalt Lake City$941
- Nicholas BreningSalt Lake City$930
- Cynthia LawlorSalt Lake City$150
- Shaun ChatelainSalt Lake City$37
- Natalie SandersSalt Lake City$0
- Cecilia DaviesSalt Lake City$0
- Kristin HueftleSalt Lake City$0
- Megan PuckettSalt Lake City$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.